Synapse - Genitourinary Oncology Service

Results (5692)

Technology-enabled longitudinal monitoring of patient-reported outcomes (PROs) to individualize care of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ICIs)

Meeting Abstract

Msaouel, P.; Van Alstine, M. L.; Oromendia, C.; Gao, J.; Wang, Y.; Siddiqui, B. A.; Siefker-Radtke, A. O.; Shah, A. Y.; Shaw, L.; Lopez, L.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials

Meeting Abstract

McQuade, J. L.; Hammers, H. J.; Furberg, H.; Engert, A.; Andre, T.; Blumenschein, G.; Tannir, N. M.; Baron, A. D.; Larkin, J.; El-Khoueiry, A. B.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer

Meeting Abstract

Mar, N.; Friedlander, T. W.; Hoimes, C. J.; Flaig, T. W.; Bilen, M. A.; Balar, A. V.; Henry, E.; Srinivas, S.; Rosenberg, J. E.; Petrylak, D. P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Kotecha, R.; Lee, C. H.; Knezevic, A.; Shah, N. J.; Carlo, M. I.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Kelly, W. K.; Danila, D. C.; Edenfield, W. J.; Aggarwal, R. R.; Petrylak, D. P.; Sartor, A. O.; Sumey, C. J.; Dorff, T. B.; Yu, E. Y.; Adra, N.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma

Meeting Abstract

Garmezy, B.; Zhang, T.; Laccetti, A. L.; Economides, M. P.; Shah, A. Y.; Tannir, N. M.; Jonasch, E.; Msaouel, P.; Zurita, A. J.; Corn, P. G.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)

Meeting Abstract

Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Changes in Ki-67 and cleaved caspase-3 (CC3) with short term androgen deprivation therapy (ADT) prior to prostatectomy as part of a trial in intermediate and high-risk prostate cancer (PC)

Meeting Abstract

Vargas Pivato de Almeida, D.; Chen, Y. B.; Autio, K. A.; Carver, B. S.; Slovin, S. F.; Danila, D. C.; Scher, H. I.; Touijer, K. A.; Rathkopf, D. E.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE)

Meeting Abstract

Chi, K. N.; Rathkopf, D. E.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Ricci, D. S.; Simon, J. S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk

Meeting Abstract

Choueiri, T. K.; Albiges, L.; Powles, T.; Scheffold, C.; Wang, F.; Motzer, R. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save